Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Dec;49(6 Suppl 5):S498-508.
doi: 10.1016/j.amepre.2015.08.013.

Post-treatment Neurocognition and Psychosocial Care Among Breast Cancer Survivors

Natasha D Buchanan  1 , Sabitha Dasari  2 , Juan L Rodriguez  3 , Judith Lee Smith  3 , M Elizabeth Hodgson  4 , Clarice R Weinberg  5 , Dale P Sandler  6
Affiliations

Post-treatment Neurocognition and Psychosocial Care Among Breast Cancer Survivors

Natasha D Buchanan et al. Am J Prev Med. 2015 Dec.

Abstract

Introduction: Chemotherapy for breast cancer has been associated with cognitive problems; however, the impact of adjuvant hormone therapy is less clear. No studies have explored provider discussions about cognitive concerns or factors associated with neurocognitive treatment. This study examined cognitive problems, factors associated with having a provider discussion, and receipt of neurocognitive treatment.

Methods: Female breast cancer survivors (N=2,537) from the Sister Study and the Two Sister Study who were at least 1 year post-treatment were surveyed in 2012 about their cancer therapies (confirmed by medical records); cognitive concerns; related provider discussions; and neurocognitive treatment. A total of 2,296 women were included in the current 2014 analysis. Extensive covariate information was also ascertained for predictive multivariate models.

Results: The prevalence of self-reported cognitive problems after treatment was 60%. Of those reporting cognitive problems, only 37% had discussed those concerns with a provider and 15% had been treated for cognitive symptoms. The odds of reported cognitive concerns that started during and after treatment were elevated for those who received only hormone therapy and no chemotherapy (OR=1.64, 95% CI=1.15, 2.33); chemotherapy and no hormone therapy (OR=5.63, 95% CI=3.52, 9.00); or both (OR=6.33, 95% CI=4.21, 9.54) compared with those reporting neither treatment.

Conclusions: The high prevalence of cognitive concerns underscores the importance of monitoring breast cancer survivors for potential neurocognitive effects of hormone and chemotherapy, discussions with survivors about those concerns, and treatment referrals. Monitoring changes over time can help to evaluate both psychosocial and neurocognitive care provided for survivors.

PubMed Disclaimer

Conflict of interest statement

No financial disclosures were reported by the authors of this paper.

Figures

Figure 1
Figure 1
Selection criteria for CTX and HTX treatment history groups.
See this image and copyright information in PMC

References

    1. Janelsins MC, Kohli S, Mohile SG, Usuki K, Ahles TA, Morrow GR. An update on cancer-and chemotherapy-related cognitive dysfunction: current status. Semin Oncol. 2011;38(3):431–438. http://dx.doi.org/10.1053/j.seminoncol.2011.03.014. - DOI - PMC - PubMed
    1. Wefel JS, Vardy J, Ahles T, Schagen SB. International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol. 2011;12(7):703–708. http://dx.doi.org/10.1016/S1470-2045(10)70294–1. - DOI - PubMed
    1. Wefel JS, Saleeba AK, Buzdar AU, Meyers CA. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2010;(14):3348–3356. http://dx.doi.org/10.1002/cncr.25098. - DOI - PubMed
    1. Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004;26(7):955–969. http://dx.doi.org/10.1080/13803390490510905. - DOI - PubMed
    1. Schilder CM, Eggens PC, Seynaeve C, et al. Neuropsychological functioning in postmenopausal breast cancer patients treated with tamoxifen or exemestane after AC-chemotherapy: cross-sectional findings from the neuropsychological TEAM-side study. Acta Oncol. 2009;48(1):76–85. http://dx.doi.org/10.1080/02841860802314738. - DOI - PubMed

Publication types

Substances